Johnson & Johnson has announced an investment of more than $1 billion to build a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, as part of its broader plan to expand US production of advanced medicines.
The new site will support the company’s portfolio and pipeline of cell therapies targeting cancer, immune-mediated and neurological diseases. Designed to incorporate advanced cell therapy manufacturing technologies, the facility is expected to strengthen domestic production capacity and support the company’s strategy to manufacture the majority of its advanced medicines within the United States.
The project is anticipated to create more than 4,000 construction jobs during the development phase and over 500 permanent positions in biomanufacturing once fully operational.
The investment adds to Johnson & Johnson’s longstanding presence in Pennsylvania, where it operates 10 facilities spanning more than 2 million square feet across manufacturing, research, distribution and office operations. The company estimates its annual economic impact in the state at approximately $10 billion.
The Pennsylvania expansion forms part of Johnson & Johnson’s previously announced $55 billion US investment commitment through early 2029, which covers manufacturing, research and development, and technology infrastructure.
The initiative reflects a wider industry trend toward bolstering domestic biomanufacturing capabilities amid growing demand for complex, next-generation therapies.
